Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Study Identifier:
D7841C00012
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Vemircopan
  • Drug: Rosuvastatin
  • Drug: Metformin
  • Drug: Levonorgestrel / Ethinyl Estradiol
  • Drug: Carbamazepine
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Vemircopan
  • Drug: Rosuvastatin
  • Drug: Metformin
  • Drug: Levonorgestrel / Ethinyl Estradiol
  • Drug: Carbamazepine
Date
Jan 2024 - Apr 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.

Trial Locations

Location
Status
Location
Research Site
Brooklyn, Maryland, United States, 21225
Status
N/A